Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122


pVACtools: a computational toolkit to identify and visualize cancer neoantigens.

Hundal J, Kiwala S, McMichael J, Miller CA, Xia H, Wollam AT, Liu CJ, Zhao S, Feng YY, Graubert AP, Wollam AZ, Neichin J, Neveau M, Walker J, Gillanders WE, Mardis ER, Griffith OL, Griffith M.

Cancer Immunol Res. 2020 Jan 6. pii: canimm.0401.2019. doi: 10.1158/2326-6066.CIR-19-0401. [Epub ahead of print]


Best practices for bioinformatic characterization of neoantigens for clinical utility.

Richters MM, Xia H, Campbell KM, Gillanders WE, Griffith OL, Griffith M.

Genome Med. 2019 Aug 28;11(1):56. doi: 10.1186/s13073-019-0666-2. Review.


Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles.

Strand MS, Krasnick BA, Pan H, Zhang X, Bi Y, Brooks C, Wetzel C, Sankpal N, Fleming T, Goedegebuure SP, DeNardo DG, Gillanders WE, Hawkins WG, Wickline SA, Fields RC.

Oncotarget. 2019 Jul 30;10(46):4761-4775. doi: 10.18632/oncotarget.27109. eCollection 2019 Jul 30.


Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma.

Johanns TM, Miller CA, Liu CJ, Perrin RJ, Bender D, Kobayashi DK, Campian JL, Chicoine MR, Dacey RG, Huang J, Fritsch EF, Gillanders WE, Artyomov MN, Mardis ER, Schreiber RD, Dunn GP.

Oncoimmunology. 2019 Jan 25;8(4):e1561106. doi: 10.1080/2162402X.2018.1561106. eCollection 2019.


WDFY4 is required for cross-presentation in response to viral and tumor antigens.

Theisen DJ, Davidson JT 4th, Briseño CG, Gargaro M, Lauron EJ, Wang Q, Desai P, Durai V, Bagadia P, Brickner JR, Beatty WL, Virgin HW, Gillanders WE, Mosammaparast N, Diamond MS, Sibley LD, Yokoyama W, Schreiber RD, Murphy TL, Murphy KM.

Science. 2018 Nov 9;362(6415):694-699. doi: 10.1126/science.aat5030.


Preclinical and clinical development of neoantigen vaccines.

Li L, Goedegebuure SP, Gillanders WE.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii11-xii17. doi: 10.1093/annonc/mdx681. Review.


Development of an adenovirus vector vaccine platform for targeting dendritic cells.

Sharma PK, Dmitriev IP, Kashentseva EA, Raes G, Li L, Kim SW, Lu ZH, Arbeit JM, Fleming TP, Kaliberov SA, Goedegebuure SP, Curiel DT, Gillanders WE.

Cancer Gene Ther. 2018 Feb;25(1-2):27-38. doi: 10.1038/s41417-017-0002-1. Epub 2017 Dec 15.


Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma.

Nywening TM, Belt BA, Cullinan DR, Panni RZ, Han BJ, Sanford DE, Jacobs RC, Ye J, Patel AA, Gillanders WE, Fields RC, DeNardo DG, Hawkins WG, Goedegebuure P, Linehan DC.

Gut. 2018 Jun;67(6):1112-1123. doi: 10.1136/gutjnl-2017-313738. Epub 2017 Dec 1.


Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity.

Zhang X, Kim S, Hundal J, Herndon JM, Li S, Petti AA, Soysal SD, Li L, McLellan MD, Hoog J, Primeau T, Myers N, Vickery TL, Sturmoski M, Hagemann IS, Miller CA, Ellis MJ, Mardis ER, Hansen T, Fleming TP, Goedegebuure SP, Gillanders WE.

Cancer Immunol Res. 2017 Jul;5(7):516-523. doi: 10.1158/2326-6066.CIR-16-0264. Epub 2017 Jun 15.


Cost Analysis of a Surgical Consensus Guideline in Breast-Conserving Surgery.

Yu J, Elmore LC, Cyr AE, Aft RL, Gillanders WE, Margenthaler JA.

J Am Coll Surg. 2017 Aug;225(2):294-301. doi: 10.1016/j.jamcollsurg.2017.03.020. Epub 2017 Apr 14.


A double-negative feedback loop between EpCAM and ERK contributes to the regulation of epithelial-mesenchymal transition in cancer.

Sankpal NV, Fleming TP, Sharma PK, Wiedner HJ, Gillanders WE.

Oncogene. 2017 Jun 29;36(26):3706-3717. doi: 10.1038/onc.2016.504. Epub 2017 Feb 13.


Personalized cancer vaccines: Targeting the cancer mutanome.

Zhang X, Sharma PK, Peter Goedegebuure S, Gillanders WE.

Vaccine. 2017 Feb 15;35(7):1094-1100. doi: 10.1016/j.vaccine.2016.05.073. Epub 2016 Jul 20. Review.


Successful Completion of the Pilot Phase of a Randomized Controlled Trial Comparing Sentinel Lymph Node Biopsy to No Further Axillary Staging in Patients with Clinical T1-T2 N0 Breast Cancer and Normal Axillary Ultrasound.

Cyr AE, Tucker N, Ademuyiwa F, Margenthaler JA, Aft RL, Eberlein TJ, Appleton CM, Zoberi I, Thomas MA, Gao F, Gillanders WE.

J Am Coll Surg. 2016 Aug;223(2):399-407. doi: 10.1016/j.jamcollsurg.2016.04.048. Epub 2016 May 20.


Mammaglobin-A is a target for breast cancer vaccination.

Kim SW, Goedegebuure P, Gillanders WE.

Oncoimmunology. 2016 Feb 26;5(2):e1069940. eCollection 2016 Feb.


Axillary Ultrasound Accurately Excludes Clinically Significant Lymph Node Disease in Patients With Early Stage Breast Cancer.

Tucker NS, Cyr AE, Ademuyiwa FO, Tabchy A, George K, Sharma PK, Jin LX, Sanati S, Aft R, Gao F, Margenthaler JA, Gillanders WE.

Ann Surg. 2016 Dec;264(6):1098-1102.


Lymphovascular space invasion and lack of downstaging after neoadjuvant chemotherapy are strong predictors of adverse outcome in young women with locally advanced breast cancer.

Khwaja SS, Ivanovich J, DeWees TA, Ochoa L, Mullen DF, Thomas M, Margenthaler JA, Cyr A, Naughton M, Sanati S, Eberlein TJ, Gillanders WE, Aft RL, Zoberi JE, Zoberi I.

Cancer Med. 2016 Feb;5(2):230-8. doi: 10.1002/cam4.586. Epub 2015 Dec 21.


Management of the Parathyroid Glands During Preventive Thyroidectomy in Patients With Multiple Endocrine Neoplasia Type 2.

Moley JF, Skinner M, Gillanders WE, Lairmore TC, Rowland KJ, Traugott AL, Jin LX, Wells SA Jr.

Ann Surg. 2015 Oct;262(4):641-6. doi: 10.1097/SLA.0000000000001464.


Developing a clinical development paradigm for translation of a mammaglobin-A DNA vaccine.

Li L, Goedegebuure SP, Fleming TP, Gillanders WE.

Immunotherapy. 2015;7(7):709-11. doi: 10.2217/imt.15.40. Epub 2015 Aug 7. No abstract available.


Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer.

Tiriveedhi V, Tucker N, Herndon J, Li L, Sturmoski M, Ellis M, Ma C, Naughton M, Lockhart AC, Gao F, Fleming T, Goedegebuure P, Mohanakumar T, Gillanders WE.

Clin Cancer Res. 2014 Dec 1;20(23):5964-75. doi: 10.1158/1078-0432.CCR-14-0059.


Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD.

Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988.


Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth.

Barbie TU, Alexe G, Aref AR, Li S, Zhu Z, Zhang X, Imamura Y, Thai TC, Huang Y, Bowden M, Herndon J, Cohoon TJ, Fleming T, Tamayo P, Mesirov JP, Ogino S, Wong KK, Ellis MJ, Hahn WC, Barbie DA, Gillanders WE.

J Clin Invest. 2014 Dec;124(12):5411-23. doi: 10.1172/JCI75661. Epub 2014 Nov 3.


Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes.

Soysal SD, Muenst S, Kan-Mitchell J, Huarte E, Zhang X, Wilkinson-Ryan I, Fleming T, Tiriveedhi V, Mohanakumar T, Li L, Herndon J, Oertli D, Goedegebuure SP, Gillanders WE.

Breast Cancer Res Treat. 2014 Oct;147(3):527-37. doi: 10.1007/s10549-014-3129-x. Epub 2014 Sep 12.


Author's response to "Letter to the editor: unvalidated antibodies and misleading results".

Muenst S, Tzankov A, Gillanders WE, Soysal SD.

Breast Cancer Res Treat. 2014 Sep;147(2):459-62. doi: 10.1007/s10549-014-3064-x. No abstract available.


Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.

Muenst S, Schaerli AR, Gao F, Däster S, Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE, Weber WP, Soysal SD.

Breast Cancer Res Treat. 2014 Jul;146(1):15-24. doi: 10.1007/s10549-014-2988-5. Epub 2014 May 20.


Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.

Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P, Godfrey JT, Qian ZR, Page AN, Maciag K, Chan EM, Silkworth W, Labowsky MT, Rozhansky L, Mesirov JP, Gillanders WE, Ogino S, Hacohen N, Gaudet S, Eck MJ, Engelman JA, Corcoran RB, Wong KK, Hahn WC, Barbie DA.

Cancer Discov. 2014 Apr;4(4):452-65. doi: 10.1158/2159-8290.CD-13-0646. Epub 2014 Jan 20.


A prospective longitudinal clinical trial evaluating quality of life after breast-conserving surgery and high-dose-rate interstitial brachytherapy for early-stage breast cancer.

Garsa AA, Ferraro DJ, DeWees TA, Deshields TL, Margenthaler JA, Cyr AE, Naughton M, Aft R, Gillanders WE, Eberlein T, Matesa MA, Ochoa LL, Zoberi I.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1043-50. doi: 10.1016/j.ijrobp.2013.09.009. Epub 2013 Oct 22.


The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.

Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE.

Breast Cancer Res Treat. 2013 Jun;139(3):667-76. doi: 10.1007/s10549-013-2581-3. Epub 2013 Jun 12.


Src homology phosphotyrosyl phosphatase-2 expression is an independent negative prognostic factor in human breast cancer.

Muenst S, Obermann EC, Gao F, Oertli D, Viehl CT, Weber WP, Fleming T, Gillanders WE, Soysal SD.

Histopathology. 2013 Jul;63(1):74-82. doi: 10.1111/his.12140. Epub 2013 May 15.


EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer.

Soysal SD, Muenst S, Barbie T, Fleming T, Gao F, Spizzo G, Oertli D, Viehl CT, Obermann EC, Gillanders WE.

Br J Cancer. 2013 Apr 16;108(7):1480-7. doi: 10.1038/bjc.2013.80. Epub 2013 Mar 21.


EpCAM modulates NF-κB signaling and interleukin-8 expression in breast cancer.

Sankpal NV, Fleming TP, Gillanders WE.

Mol Cancer Res. 2013 Apr;11(4):418-26. doi: 10.1158/1541-7786.MCR-12-0518. Epub 2013 Feb 1.


PTP1B expression is an independent positive prognostic factor in human breast cancer.

Soysal S, Obermann EC, Gao F, Oertli D, Gillanders WE, Viehl CT, Muenst S.

Breast Cancer Res Treat. 2013 Jan;137(2):637-44. doi: 10.1007/s10549-012-2373-1. Epub 2012 Dec 16.


Endoscopic and robotic thyroidectomy for cancer.

Mitchem JB, Gillanders WE.

Surg Oncol Clin N Am. 2013 Jan;22(1):1-13, v. doi: 10.1016/j.soc.2012.08.009. Review.


Cosmetic analysis following breast-conserving surgery and adjuvant high-dose-rate interstitial brachytherapy for early-stage breast cancer: a prospective clinical study.

Garsa AA, Ferraro DJ, DeWees T, Margenthaler JA, Naughton M, Aft R, Gillanders WE, Eberlein T, Matesa MA, Zoberi I.

Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):965-70. doi: 10.1016/j.ijrobp.2012.08.027. Epub 2012 Oct 9.


Disease recurrence in sentinel node-positive breast cancer patients forgoing axillary lymph node dissection.

Cyr A, Gao F, Gillanders WE, Aft RL, Eberlein TJ, Margenthaler JA.

Ann Surg Oncol. 2012 Oct;19(10):3185-91. doi: 10.1245/s10434-012-2547-4. Epub 2012 Aug 14.


Cross-dressed CD8α+/CD103+ dendritic cells prime CD8+ T cells following vaccination.

Li L, Kim S, Herndon JM, Goedegebuure P, Belt BA, Satpathy AT, Fleming TP, Hansen TH, Murphy KM, Gillanders WE.

Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12716-21. doi: 10.1073/pnas.1203468109. Epub 2012 Jul 16.


Analysis of fat necrosis after adjuvant high-dose-rate interstitial brachytherapy for early stage breast cancer.

Garsa AA, Ferraro DJ, Dewees T, Margenthaler JA, Naughton M, Aft R, Gillanders WE, Eberlein T, Matesa MA, Zoberi I.

Brachytherapy. 2013 Mar-Apr;12(2):99-106. doi: 10.1016/j.brachy.2012.04.005. Epub 2012 Jun 20.


Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells.

Tiriveedhi V, Fleming TP, Goedegebuure PS, Naughton M, Ma C, Lockhart C, Gao F, Gillanders WE, Mohanakumar T.

Breast Cancer Res Treat. 2013 Feb;138(1):109-18. doi: 10.1007/s10549-012-2110-9. Epub 2012 Jun 8.


Compromised margins following mastectomy for stage I-III invasive breast cancer.

Yu J, Al Mushawah F, Taylor ME, Cyr AE, Gillanders WE, Aft RL, Eberlein TJ, Gao F, Margenthaler JA.

J Surg Res. 2012 Sep;177(1):102-8. doi: 10.1016/j.jss.2012.03.046. Epub 2012 Apr 10.


Positive margin rates following breast-conserving surgery for stage I-III breast cancer: palpable versus nonpalpable tumors.

Atkins J, Al Mushawah F, Appleton CM, Cyr AE, Gillanders WE, Aft RL, Eberlein TJ, Gao F, Margenthaler JA.

J Surg Res. 2012 Sep;177(1):109-15. doi: 10.1016/j.jss.2012.03.045. Epub 2012 Apr 10.


Comparison of accelerated partial breast irradiation via multicatheter interstitial brachytherapy versus whole breast radiation.

Ferraro DJ, Garsa AA, DeWees TA, Margenthaler JA, Naughton M, Aft R, Gillanders WE, Eberlein T, Matesa MA, Zoberi I.

Radiat Oncol. 2012 Mar 29;7:53. doi: 10.1186/1748-717X-7-53.


Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.

Porembka MR, Mitchem JB, Belt BA, Hsieh CS, Lee HM, Herndon J, Gillanders WE, Linehan DC, Goedegebuure P.

Cancer Immunol Immunother. 2012 Sep;61(9):1373-85. doi: 10.1007/s00262-011-1178-0. Epub 2012 Jan 4.


Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion.

Sankpal NV, Mayfield JD, Willman MW, Fleming TP, Gillanders WE.

Breast Cancer Res. 2011;13(6):R124. doi: 10.1186/bcr3070. Epub 2011 Dec 1.


Identification of HLA-A24-restricted CD8(+) cytotoxic T-cell epitopes derived from mammaglobin-A, a human breast cancer-associated antigen.

Tiriveedhi V, Sarma NJ, Subramanian V, Fleming TP, Gillanders WE, Mohanakumar T.

Hum Immunol. 2012 Jan;73(1):11-6. doi: 10.1016/j.humimm.2011.10.017. Epub 2011 Oct 23.


Photoacoustic microscopy of tyrosinase reporter gene in vivo.

Krumholz A, Vanvickle-Chavez SJ, Yao J, Fleming TP, Gillanders WE, Wang LV.

J Biomed Opt. 2011 Aug;16(8):080503. doi: 10.1117/1.3606568.


Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.

Fisher CS, Ma CX, Gillanders WE, Aft RL, Eberlein TJ, Gao F, Margenthaler JA.

Ann Surg Oncol. 2012 Jan;19(1):253-8. doi: 10.1245/s10434-011-1877-y. Epub 2011 Jul 2.


Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer.

Goedegebuure P, Mitchem JB, Porembka MR, Tan MC, Belt BA, Wang-Gillam A, Gillanders WE, Hawkins WG, Linehan DC.

Curr Cancer Drug Targets. 2011 Jul;11(6):734-51. Review.


Correlates of fear of cancer recurrence in women with ductal carcinoma in situ and early invasive breast cancer.

Liu Y, Pérez M, Schootman M, Aft RL, Gillanders WE, Jeffe DB.

Breast Cancer Res Treat. 2011 Nov;130(1):165-73. doi: 10.1007/s10549-011-1551-x. Epub 2011 May 8.


Breast cancer in elderly women (≥ 80 years): variation in standard of care?

Cyr A, Gillanders WE, Aft RL, Eberlein TJ, Margenthaler JA.

J Surg Oncol. 2011 Mar 1;103(3):201-6. doi: 10.1002/jso.21799. Epub 2010 Nov 23.


Cancer genome sequencing and its implications for personalized cancer vaccines.

Li L, Goedegebuure P, Mardis ER, Ellis MJ, Zhang X, Herndon JM, Fleming TP, Carreno BM, Hansen TH, Gillanders WE.

Cancers (Basel). 2011 Nov 25;3(4):4191-211. doi: 10.3390/cancers3044191.


Management of cervical nodal metastasis detected on I-131 scintigraphy after initial surgery of well-differentiated thyroid carcinoma.

Creach KM, Gillanders WE, Siegel BA, Haughey BH, Moley JF, Grigsby PW.

Surgery. 2010 Dec;148(6):1198-204; discussion 1204-6. doi: 10.1016/j.surg.2010.09.006.


Supplemental Content

Loading ...
Support Center